Dr. Levitt has >35 years of experience as a physician-scientist and pharmaceuticals development including leadership in development stage and global commercial biopharmaceuticals. He is a serial inventor with >25 issued patents and entrepreneur having created and/or led multiple biopharmaceutical companies. Dr. Levitt is founder of Onspira Therapeutics where he served as CSO and board member that was sold to Sumitomo in 2019. His experience also includes Director Medical Affairs, Commercial Operations, CSL Behring; Chief Executive Officer, President and board member of Genera Corporation (NASDAQ). He has served as Principal Investigator multiple competitive Awards including the DoD, NIH, Cystic Fibrosis and Coulter Foundations
Mr. Barone has >30 years of business development and commercial operations leadership for public and private biopharma companies. His extensive licensing and M&A experience includes numerous value creating transactions as-well-as providing in-house counsel services. Founding member of Reliant Pharmaceuticals, co-founded Essential Pharmaceuticals and Onspira Therapeutics, all of which had successful exits.
Mr. Rongen is a serial entrepreneur and R&D / Commercial Development leader with extensive experience across many therapeutic areas and functions. He founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB); and he was integral to the development and commercialization of blockbuster products such as Humira® and Lovaza®.
Dr. Rogers is a physician, serial entrepreneur, professor, and hospital administrator, who brings leadership and expertise in health care and the biopharmaceutical industry spanning both private and public sectors with significant board and operational experience. Most notably, Dr. Rogers was CEO of Duke Hospital and Health Network before joining Perkin Elmer as Chief Technology Officer (NYSE:PKI) where he was in charge of the company’s human genome sequencing program, amongst other responsibilities. He then moved into medical venture capital becoming CEO of Paramount Capital.